Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer
The FEBS Journal · 2023-02 · 290 (3) · 763-779
DOI: 10.1111/febs.16614 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 11.09.2022. Verfasst von Yin Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Autophagic Cell Death. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Medicinal Chemical Biology.
Abstract (Originalsprache)
Dysregulation of G6PD involved in the pentose phosphate pathway (PPP) is known to promote tumorigenesis. The PPP plays a pivotal role in meeting the anabolic demands of cancer cells. However, the detailed underlying molecular mechanisms of targeting the G6PD‐regulated PPP in breast cancer remain unclear. In this study, we aimed to elucidate the molecular pathways mediating the effects of G6PD on cancer progression. Clinical sample analysis found that the expression of G6PD in breast cancer patients was higher than that in normal controls, and patients with higher G6PD expression had poor survival. Gene knockdown or inhibition of G6PD by 6‐AN in MCF‐7 and MDA‐MB‐231 cells significantly decreased cell viability, migration, and colony formation ability. G6PD enzyme activity was inhibited by 6‐AN treatment, which caused a transient upregulation of ROS. The elevated ROS was independent of cell apoptosis and thus associated with abnormal activated autophagy. Accumulated ROS levels induced autophagic cell death in breast cancer. Inhibition of G6PD suppresses tumour growth in preclinical models of breast cancer. Our results indicate that targeting the G6PD‐regulated PPP could restrain tumours in vitro and in vivo , inhibiting G6PD caused cell death by over‐activating autophagy, therefore leading to inhibited proliferation and tumour formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
- Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, China.
- Department of Immunology & Wu Lien-Teh Institute & Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University& Heilongjiang Academy of Medical Science, China.
- Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
ORCID-Profile: Chenggang Li
Förderung
- National Natural Science Foundation of China
- State Key Laboratory of Medicinal Chemical Biology
Zitieren
APA
Li, Y., Zheng, F., Zhang, Y., Lin, Z., Yang, J., Han, X., Feng, Y., Pei, X., Li, F., Liu, Q., Yan, L., Li, T., Zhang, Y., Li, D., Fu, Z., Wang, C., Sun, Q., & Li, C. (2023). Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer. The FEBS Journal, 290(3), 763-779. https://doi.org/10.1111/febs.16614
Vancouver
Li Y, Zheng F, Zhang Y, Lin Z, Yang J, Han X, et al. Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer. The FEBS Journal. 2023;290(3):763-779. doi:10.1111/febs.16614
BibTeX
@article{Li2023,
author = {Li, Yin and Zheng, Fangxu and Zhang, Yupeng and Lin, Zhoujun and Yang, Juan and Han, Xiao and Feng, Ya and Pei, Xiaolin and Li, Fei and Liu, Qiao and Yan, Lizhong and Li, Tianjiao and Zhang, Yifan and Li, Ding and Fu, Zhenkun and Wang, Changjun and Sun, Qiang and Li, Chenggang},
title = {Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer},
journal = {The FEBS Journal},
year = {2023},
volume = {290},
number = {3},
pages = {763--779},
doi = {10.1111/febs.16614}
}
EUVIMED